Equity Profile

ARQT

Arcutis Biotherapeutics, Inc.

Health CareBiotechnology$3.4B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Investors will look for signs of revenue growth to gauge the company's market traction and product acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARQT Q2-2026 Earnings Preview

Context

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases. With a market cap of $3 billion, it operates in the health care sector, aiming to address unmet medical needs in dermatology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.67%

Avg Stock Reaction

+2.77%

Last Quarter Recap

In Q1-2026, Arcutis reported an EPS of -$0.09, missing estimates significantly. Despite this, the stock rose 3.20% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as the company has a history of beating EPS estimates, but recent performance raises concerns about revenue growth.

Bull Case

If Arcutis can demonstrate strong product uptake and improved revenue this quarter, it could lead to a significant positive reaction from investors.

Bear Case

On the other hand, continued losses or disappointing revenue could reinforce skepticism about the company's growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be critical in assessing the company's profitability and could significantly influence investor sentiment.

What are the revenue figures for this quarter?

Revenue growth is essential for validating the company's market strategy and product acceptance, impacting future projections.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Arcutis to achieve a turnaround in profitability this quarter, given its history of beating EPS estimates.

Supporting Evidence

The company has an 88% EPS beat rate historically, indicating a strong potential for positive surprises.

Options pricing suggests a significant move, reflecting uncertainty that could favor a positive outcome.

Recent insider buying activity indicates confidence in the company's future performance.

Key Risk

If EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Arcutis can achieve profitability and revenue growth, which are crucial for its long-term success.

Bull Confirmed If

A positive EPS surprise of $0.05 or better would confirm the bull case.

Bear Confirmed If

An EPS of -$0.15 or worse would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.36%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±18.4% while ARQT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

62.0%

Calls (13K)P/C Ratio: 0.14Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcutis beats expectations, history suggests the stock could rise by around 2.7%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of around 3.2%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product launches or market penetration strategies.
2Management's commentary on cost management and operational efficiency.
3Insights into competitive landscape and market share.
4Details on research and development progress for upcoming therapies.
5Any changes in guidance or outlook for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Investors will look for signs of revenue growth to gauge the company's market traction and product acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARQT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.67%

Avg Stock Reaction

+2.77%

Last Quarter Recap

In Q1-2026, Arcutis reported an EPS of -$0.09, missing estimates significantly. Despite this, the stock rose 3.20% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as the company has a history of beating EPS estimates, but recent performance raises concerns about revenue growth.

Bull Case

If Arcutis can demonstrate strong product uptake and improved revenue this quarter, it could lead to a significant positive reaction from investors.

Bear Case

On the other hand, continued losses or disappointing revenue could reinforce skepticism about the company's growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be critical in assessing the company's profitability and could significantly influence investor sentiment.

What are the revenue figures for this quarter?

Revenue growth is essential for validating the company's market strategy and product acceptance, impacting future projections.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Arcutis to achieve a turnaround in profitability this quarter, given its history of beating EPS estimates.

Supporting Evidence

The company has an 88% EPS beat rate historically, indicating a strong potential for positive surprises.

Options pricing suggests a significant move, reflecting uncertainty that could favor a positive outcome.

Recent insider buying activity indicates confidence in the company's future performance.

Key Risk

If EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Arcutis can achieve profitability and revenue growth, which are crucial for its long-term success.

Bull Confirmed If

A positive EPS surprise of $0.05 or better would confirm the bull case.

Bear Confirmed If

An EPS of -$0.15 or worse would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.36%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±18.4% while ARQT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

62.0%

Calls (13K)P/C Ratio: 0.14Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcutis beats expectations, history suggests the stock could rise by around 2.7%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of around 3.2%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product launches or market penetration strategies.
2Management's commentary on cost management and operational efficiency.
3Insights into competitive landscape and market share.
4Details on research and development progress for upcoming therapies.
5Any changes in guidance or outlook for the next quarter.